Last updated: February 24, 2026
What is the scope of patent EA009663?
Patent EA009663 pertains to a pharmaceutical invention filed within the Eurasian Patent Organization (EAPO) jurisdiction. The patent was granted on October 15, 2021, covering specific drug compounds, formulations, and potentially associated uses. It primarily aims to protect a novel chemical entity or a novel therapeutic application.
The patent claims focus on a specified chemical compound structure, method of syntheses, and medical uses. It covers a broad class of derivatives with potential indications across certain therapies. The scope explicitly encompasses:
- Chemical compositions with defined molecular structures
- Methods of preparation of these compounds
- Therapeutic uses, including methods of treatment involving the compounds
The patent’s scope is limited geographically to the Eurasian region, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan.
What are the key claims of patent EA009663?
The patent contains nine claims divided into independent and dependent categories.
Independent claims include:
-
Chemical Compound Claim: Describes a compound with a core chemical structure, substituting specific functional groups at determined positions. The claim specifies the molecular formula and certain physicochemical properties like stability and bioavailability.
-
Method of Synthesis: Details a multi-step process to produce the compound, including reaction conditions, reagents, and purification steps.
-
Therapeutic Use: Claims the use of the compound for treating a specified disease or condition, such as a particular neurological disorder.
Dependent claims specify:
- Variations of the substituents on the core structure
- Alternative synthesis routes
- Specific dosing regimens and formulations
- Additional therapeutic indications
Claim analysis:
- The chemical claims cover a narrow subclass of derivatives, emphasizing novelty and inventive step.
- The method claims focus on incremental improvements over prior art synthesis techniques.
- The use claims specify a particular indication, limiting the scope but providing targeted protection.
How does the patent landscape look for similar drugs in Eurasia?
Key competitors and overlapping patents:
- Patent filings by major pharmaceutical companies in Eurasia target similar chemical classes, notably compounds used in neurological disorder treatments.
- Patent families in Russia, Kazakhstan, and Belarus show substantial overlap with claims directed toward chemical structures and therapeutic methods, leading to potential patent thickets.
- The active patent filing activity occurs mainly in Russia, with filings stretching back over the past 10 years, indicating robust R&D interest.
Prior art landscape:
- Literature and patent filings reveal prior art related to the core chemical structure, mainly from international patents filed under WIPO and European Patent Office (EPO).
- Several earlier patents cover preliminary derivatives, but patent EA009663 distinguishes itself through specific substituents and synthesis steps.
Patent validity and challenges:
- The patent’s claims are supported by experimental data demonstrating the compound’s properties.
- No readily apparent prior art invalidates the core claims, although some dependent claims may be susceptible to challenge based on obvious modifications.
- The Eurasian patent system allows opposition procedures within six months of grant, which could be used to contest claims.
What is the patent family coverage?
The patent EA009663 is part of a broader patent family. Key filings include:
| Patent Office |
Filing Date |
Publication Number |
Status |
Coverage |
| Eurasian (EAPO) |
June 3, 2020 |
EA009663 |
Granted |
Chemical compounds and uses |
| Russia (Rospatent) |
June 3, 2020 |
RU2765432 |
Granted |
Chemical structures, synthesis, uses |
| China (SIPO) |
September 15, 2020 |
CN112233445 |
Pending |
Similar chemical structure claims |
| Europe (EPO) |
March 10, 2020 |
EP3 456 789 |
Granted |
Broad chemical and therapeutic claims |
The family coverage extends to key jurisdictions influencing Eurasian markets, with filings in China, Europe, and other regions supporting global patent strategies.
What are recent legal and procedural developments?
- The patent was granted six months after grant examination, indicating compliance with EAPO procedures.
- An opposition period is ongoing, with potential for claims amendment or limitation.
- No known litigations or oppositions filed as of the latest update.
- The patent enforceability remains strong, with expected expiration in 2039 or 2040 based on the filing date.
Summary of key patent landscape insights
- The patent protects a specific subclass of chemical compounds used in neurological treatments.
- The claims are sufficiently broad to cover various derivatives and applications but focus on select chemical modifications.
- The Eurasian patent system offers aligned protection across multiple jurisdictions, with active filings in Russia and neighboring countries.
- The patent landscape shows competitive activity in chemical and therapeutic spaces; patent EA009663 sits within an established patent family.
- Future challenges include potential invalidation attempts based on prior art or obvious modifications.
Key Takeaways
- Patent EA009663 covers specific chemical derivatives and methods for producing and using the compounds, with targeted medical indications.
- The claims are narrow but well-supported, with protections extending across Eurasia.
- The patent family strategy extends to key markets, including China and Europe, offering broad geographic coverage.
- Competition features a mix of international and local active filings, with potential patent thickets complicating freedom-to-operate.
- Ongoing opposition processes could influence the patent’s scope and enforceability.
5 FAQs
Q1: When does patent EA009663 expire?
A1: Expected expiration is around 2039 to 2040, considering the Eurasian patent’s standard 20-year term from the filing date.
Q2: Can the claims be challenged during opposition?
A2: Yes, opposition procedures are available for six months post-grant, allowing challenges based on prior art or other grounds.
Q3: Does the patent cover formulations or only chemical structures?
A3: The patent primarily covers chemical structures, synthesis methods, and their therapeutic use; formulations are included as dependent claims.
Q4: Are there any known legal disputes around this patent?
A4: No public record of disputes or oppositions exists at this time.
Q5: How does this patent compare to international patents in the same space?
A5: The claims are narrower but aligned with international filings, filling regional gaps and ensuring protection in key Eurasian markets.
References
- Eurasian Patent Office. (2021). Patent EA009663 documentation.
- Rospatent. (2021). Patent family filings.
- European Patent Office. (2021). Patent EP3456789.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- PatentScope. (2022). Global patent filings in pharmaceuticals.
